{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"82"},{"groupId":"OG003","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"description":"An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. Graded according to NCI CTCAE (Version 4.03) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.","groups":[{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Phase 1b - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG001","title":"Phase 1b - ACY-1215 Dose Level 3"},{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG002","title":"Phase 2 - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG003","title":"Phase 2 - ACY-1215 Dose Level 3"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in the Safety population.","reportingStatus":"POSTED","timeFrame":"From first dose until 30 days after last dose of study drug (assessed for an average of approximately 55 weeks to a maximum of approximately 456 weeks)","title":"Number of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}